Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-08
J
Jennifer S. Guimbellot
Associate Professor
Also affiliated: Arkansas Children's Hospital (2024–2026); University of Alabama at Birmingham Hospital (2020–2022); University of Alabama (2018); University of Washington (2023); University of Arkansas Medical Center (2025–2026); Cystic Fibrosis Foundation (2024); University of Alabama at Birmingham (2003–2026); University of North Carolina Hospitals (2013); Pulmonary Associates (2018); Arkansas Children's Nutrition Center (2026)
Faculty Researcher
19 h-index
70 pubs
1,010 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jennifer S. Guimbellot's research focuses on the study and treatment of cystic fibrosis (CF), particularly the efficacy and application of CFTR modulator therapies. She has investigated the use of elexacaftor/tezacaftor/ivacaftor in CF lung transplant recipients and explored the relationship between CFTR function, clinical response, and organoid swelling in patients undergoing modulator treatment. Her work also includes the quantitation of these triple combination therapies in human plasma and cellular lysates, as well as examining drug concentrations in CF patients. Guimbellot has explored genetic approaches, such as prime editing for CFTR mutation correction in induced pluripotent stem cells and airway epithelial cells. Her research extends to clinical outcomes, including the evaluation of children with CF screen-positive, inconclusive diagnoses, and CFTR-related metabolic syndrome. She also investigates the impact of social determinants of health, examining electronic screening for unmet social needs in pediatric pulmonary clinics and its association with health outcomes. Guimbellot has co-authored 69 publications, accumulating 1,001 citations, and holds an h-index of 19. She collaborates with researchers at the University of Arkansas for Medical Sciences, including A. Chalamalla and Saly Abouelenein.
Metrics
- h-index: 19
- Publications: 70
- Citations: 1,010
Selected Publications
-
Shifting Nutrition Paradigms: Changing Attitudes Towards Diet and Body Perceptions Among People With CF in the Era of Highly Effective Modulators (2026)
-
Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis (2026)
-
Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy (2026)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis (2025)
-
P018 Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing (2025)
-
One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators (2025)
-
Tobacco Smoke Exposure Decreases Longitudinal Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (2025)
-
Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor (2025)
-
Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant (2025)
-
Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial (2024)
-
Literary evidence of the impact of nonbiological risk factors on CRMS/CFSPID: A scoping review (2024)
-
Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL) (2024)
Collaboration Network
Top Collaborators
A. Chalamalla
University of Alabama at Birmingham
7 shared publications
In database
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Showing 5 of 7 shared publications
Edward P. Acosta
University of Alabama at Birmingham (US)
5 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
Saly Abouelenein
University of Arkansas for Medical Sciences
5 shared publications
In database
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- P018 Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Natalie R. Rose
University of Alabama at Birmingham (US)
4 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Literary evidence of the impact of nonbiological risk factors on CRMS/CFSPID: A scoping review
- Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy
Elizabeth Baker
University of Alabama at Birmingham (US)
4 shared publications
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor
- EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis
Kathleen J. Ramos
University of Washington (US)
4 shared publications
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Kevin J. Ryan
University of Alabama at Birmingham (US)
3 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor
Alexander E. Dowell
University of Alabama at Birmingham (US)
2 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
Steven M. Rowe
Cystic Fibrosis Foundation (US)
2 shared publications
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
S. Vamsee Raju
Cystic Fibrosis Foundation (US)
2 shared publications
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
Gabriela R. Oates
University of Alabama at Birmingham (US)
2 shared publications
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Tobacco Smoke Exposure Decreases Longitudinal Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis
E.P. Costa
University of Alabama System (US)
2 shared publications
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Bryan Garcia
1 shared publication
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
Stefanie Krick
Cystic Fibrosis Foundation (US)
1 shared publication
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
Jonathan Bergeron
1 shared publication
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
Similar Researchers
Based on overlapping research topics
L J Lesko
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Metabolism and Genetic Disorders
VK Todorova
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Metabolism and Genetic Disorders
Bridgett Knox
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Metabolism and Genetic Disorders
Serena Van
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Drug Transport and Resistance Mechanisms
Landon Bruich
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Metabolism and Genetic Disorders
A. Chalamalla
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Health Disparities and Outcomes